Lee K, et al. – In order to ascertain germline BRCA mutations in pancreatic ductal adenocarcinoma (PDAC) patients with Asian ethnicity, the efficiency of risk criteria based on personal or family history of breast and ovarian cancer was appraised. For screening germline BRCA mutations in Asian PDAC patients, personal or family history of breast or ovarian cancers was a feasible, cost-effective risk categorization, as 10% of this population had the pathogenic mutation.